Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit
|
|
- Ezra Lawrence
- 8 years ago
- Views:
Transcription
1 SUPPLEMENT ARTICLE Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit Roberto Muga, Arantza Sanvisens, José Manuel Egea, Jordi Tor, and Celestino Rey-Joly Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain In a cross-sectional study of 1111 injection drug users (IDUs) admitted to a hospital detoxification unit between 1987 and 2001, characteristics of substance abuse and blood samples were obtained at study entry. The median age at admission was 27 years, the median age at first injection of drugs was 19 years, and the median duration of injection drug use was 84 months. Overall prevalence of human immunodeficiency virus (HIV) infection was 60% (58% in men, 66% in women; P p.026). Age at start of and duration of injection drug use were associated with HIV infection ( P!.001). The rate of HIV infection in persons with short duration of drug use (!24 months) was higher among women (45%) than among men (21%) ( P p.002). The prevalence of HIV infection among IDUs!21 years old at first use of injection drugs and among patients reporting!48 months of injection drug use was significantly lower in those who started injection drug use after 1992 (19% vs. 53% of IDUs; odds ratio, 4.42; 95% confidence interval, ). Awareness of acquired immunodeficiency syndrome, preventive measures, and substance abuse treatment have contributed to the stabilization of the HIV epidemic. The higher prevalence of HIV infection among women IDUs and among young IDUs who recently began injecting drugs emphasizes the need to target HIV-transmission risk reduction interventions early. Since 1981, a total of 61,028 people have received a diagnosis of AIDS in Spain [1]. In fact, the pairing of drug abuse and HIV infection is one of the most critical public health problems in our country because every 2 out of 3 AIDS cases are related to injection drug use. The sudden onset of the HIV epidemic coincided with the spread of injection heroin use in Spain in the late 1970s [2, 3]. The expansion of injection heroin use and the lack of knowledge of the modes of HIV transmission was of fundamental importance to the spread of HIV at the beginning of the 1980s; by 1993, Spain had the highest cumulative incidence of AIDS cases in Western Europe. Grant support: Fondo de Investigación Sanitaria (FIS), Ministry of Health, Spain (FIS 00/0294, FIS G03/005). Reprints or correspondence: Dr. Roberto Muga, Dept. of Internal Medicine, Rm. 806, Hospital Universitari Germans Trias i Pujol, Carretera Canyet s/n, Badalona, Barcelona, Spain (rmuga@ns.hugtip.scs.es). Clinical Infectious Diseases 2003; 37(Suppl 5):S by the Infectious Diseases Society of America. All rights reserved /2003/3712S5-0014$15.00 Previous studies have demonstrated that 2 groups, injection drug users (IDUs) who start injection drug use at an early age and women, are at increased risk of HIV infection, even in areas where extensive prevention and harm reduction programs have been implemented [4 9]. From a public health perspective, the monitoring of the prevalence of HIV infection and the identification of target groups of young IDUs who recently started injecting drugs are essential for the development of effective health interventions [10]. In our setting, the scarcity of prospective studies on the incidence of HIV infection reinforces the need to analyze the temporal trends of prevalence. Furthermore, the decrease in the number of cases of AIDS in Spain since 1997 may be attributed not just to the introduction of HAART but also to a lower rate of infection among IDUs, because injection drug use is the main route of HIV transmission. The objective of this study was to monitor trends in the prevalence of HIV infection in a hospital detoxification unit where IDUs with the most severe patterns of drug use were referred over the last 15 years. S404 CID 2003:37 (Suppl 5) Muga et al.
2 PATIENTS, MATERIALS, AND METHODS Study design and study population. This was a cross-sectional study of IDUs admitted to a 4-bed detoxification unit in a tertiary hospital in Badalona (metropolitan Barcelona) between February 1987 and December Patients were referred from outpatient clinics for substance abuse treatment. Further details regarding the criteria for admission and the characteristics of detoxification treatment have been published elsewhere [11]. Briefly, the majority of subjects included in this study were heroin users who injected the drug an average of 3 times a day and showed clear criteria of heroin dependence. At admission, subjects provided blood samples for determination of HIV (confirmed by EIA and Western blot), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), and syphilis (confirmed by rapid plasma reagin [RPR] and microhemagglutination [MHA-TP] tests) and completed an interviewer-administered (face-to-face) questionnaire regarding demographic and drug use characteristics. Date of and age at first injection of drugs and duration of injection drug use were specifically asked for during the interview. For the purpose of this study, patients who were admitted to the detoxification unit 11 time between 1987 and 2001 were assessed only at their first admission. Statistical analysis. Data analysis was done with Student s t test or analysis of variance and the x 2 test. The magnitude of the univariate associations for HIV infection and variable predictors were measured by odds ratios with 95% confidence intervals. P!.05 was considered statistically significant. Statistical analysis was done with SPSS version 11.5 (SPSS) and Epi Info version 6 (Centers for Disease Control) packages. RESULTS Table 1. Characteristics of 1111 injection drug users at admission to a hospital detoxification unit, February 1987 to December Characteristic Value Sex Male 903/1111 (81) Female 208/1111 (19) Injection drug use a Age at start, median years 19 Date of start, median May 1985 Duration, median months 84 Age at hospital admission, median years 27 Infection status HIV positive 661/1111 (60) HCV positive b 325/354 (92) HBsAg positive 77/973 (8) Positive for syphilis 23/691 (3) NOTE. Data are no. of patients with characteristic/no. tested (%), unless indicated otherwise. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus. a Data for 1104 patients. b Testing for HCV antibodies was done after September From February 1987 through December 2001, 1144 IDUs were admitted to the detoxification unit. Thirty-three patients (2.9%) did not provide a blood sample to test for HIV, so the population of the study was 1111 patients. Of these, 39% of patients had been incarcerated before admission. Seventy-nine percent of patients reported a temporary cessation of injection drug use (median duration of cessation, 14 months; interquartile range [IQR], 6 34 months). For 7 of the 1111 cases, we do not have information regarding age at and date of first injection of drugs and duration of injection drug use. Thirty-four percent of patients began injection drug use at age!18, 35% between the ages of 18 and 21, and 31% at age 21. The duration of injection drug use before admission was!24 months for 16% of the patients, months for 16%, and 148 months for 68%. Table 1 shows the characteristics of the patient population at entry: 81% of patients were men, the median age at admission was 27 years (IQR, years), and the median duration of injection drug use was 84 months (IQR, months). Globally, 60% of patients were HIV-positive, 92% were HCV-positive, 8% were HBsAg-positive, and 3% had positive results of RPR and MHA-TP testing. HIV-positive IDUs had started injection drug use earlier (mean, January 1984) than had those who were HIV-negative (mean, June 1988). The proportion of women was higher among HIV-positive subjects than among those who were HIVnegative (21% vs. 16% of patients; P p.03). Patients age at the start of injection drug use was younger among HIV-positive IDUs than among HIV-negative IDUs (mean ages, vs years; P!.001). Also, the duration of injection drug use was significantly longer among HIV-positive IDUs than among those who were HIV-negative (mean duration, vs months; P!.001). The prevalences of HCV infection and of positive serologic test results for syphilis (as determined by RPR and MHA-TP tests) were significantly higher in HIV-positive IDUs (98% and 4% of patients, respectively) than in HIV-seronegative IDUs (86% and 2%) ( P!.001). Prevalence of HBsAg positivity was similar in HIV-positive (8% of patients) and HIV-negative (7%) IDUs ( P p.47). As determined by use of similar recruitment strategies and interviewer-administered questionnaires, the characteristics of patients have changed over the last 15 years. Age at the start of injection drug use, duration of injection drug use, and age at admission have significantly increased for those admitted between 1997 and 2001 (table 2). However, the proportion of male IDUs remained stable and the prevalence of HIV de- HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S405
3 Table 2. Characteristics of 1111 injection drug users at admission to a hospital detoxification unit, by calendar periods of admission, February 1987 to December Characteristic (n p 491) Period of admission (n p 390) (n p 230) Male, % of patients Date of birth, mean May 1963 Jan 1966 Jan 1968!.001 Injection drug use Age at start, mean years !.001 Duration, mean months !.001 Age at admission, mean years !.001 Infection status, % of patients HIV positive !.001 HCV positive NA 93 b HBsAg positive Positive for syphilis NOTE. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NA, not available. a P for comparison of calendar periods of admission. b Testing for HCV antibodies was performed after September P a creased from 70% to 48%, despite the fact that the patients admitted between 1997 and 2001 had a longer duration of injection drug use. In relation to year of first injection of drugs, 61.4% of subjects (678 of 1104 patients) started using injection drugs before 1987, whereas 13.7% (151 of 1104) started after Table 3 shows the association of HIV-infection prevalence with calendar periods of start of injection drug use (!1987, , 11992), sex, and age at first injection of drugs. Despite a significant decrease in the prevalence of HIV infection in the period later than 1992, 25% of those IDUs who started injection drug use before the age of 18 and 35% of the women with short duration of injection drug use were HIV positive. Figures 1 3 show the downward trend in HIV-infection prevalence with regard to the year of starting injection drug use, sex, and age at first injection drug use in persons with comparable durations of injection. Patients starting injection drug use after 1992, men, and persons 121 years old when they started using injection drugs show less prevalence of HIV infection than do those starting before 1992, females, and IDUs!18 years old when they began using injection drugs. Table 4 shows the odds of being HIV positive according to sex and age at start of injection drug use, after controlling for the duration ( 48 months or 148 months) and the calendar period (1992 and before, or after 1992) of injection drug use. IDUs who reported 14 years of injection drug use and first parenteral use of Table 3. Prevalence of HIV infection among 1111 injection drug users at admission to a hospital detoxification unit in 3 calendar periods, according to sex and to age at the start of injection drug use. Characteristic No. (%) of patients positive for HIV, by period injection drug use started Before 1987 (n p 678) (n p 275) After 1992 (n p 151) Sex Male 402 (74) 96 (42) 22 (18)!.001 Female 100 (76) 27 (56) 9 (35)!.001 Age at start of injection drug use, years! (76) 36 (54) 4 (25)! (77) 44 (43) 9 (27)! (64) 43 (40) 18 (18)!.001 a P for comparison of periods of starting injection drugs. P a S406 CID 2003:37 (Suppl 5) Muga et al.
4 Figure 1. Prevalence of HIV (% of patients infected) according to calendar periods of start of injection drug use and duration of injection drug use. (*), P for comparison of HIV-infection prevalence by period of starting injection drug use within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 76% if they started injecting before 1987, 49% if they started between 1987 and 1992, and 33% if they started after 1992; P p.003). (**), P for comparison of HIV-infection prevalence by period of starting injection drug use according to 3 categories of duration of injection drug use (i.e., prevalences of HIV in those starting injection drug use before 1987 and reporting 14 years, 2 4 years, or!2 years of injection drug use were 76%, 60%, and 48%, respectively; P p.001). drugs before 1992 had an increased probability of being HIVpositive than did those with similar characteristics who started injecting drugs after 1992 (OR, 5.39; 95% CI, ). DISCUSSION During 15 years, we have monitored the prevalence of HIV in hard-line IDUs, which has allowed us to confirm the stabilization of the epidemic regarding the main category of transmission in Spain. In this respect, the decrease in the number of cases of AIDS in Spain since 1997 may have not been due merely to the effectiveness of HAART but also to the reduction in the number of new HIV-infected IDUs. Recently, the European Monitoring Centre for Drugs and Drug Addiction (Lisbon) has reported similar trends in HIV infection among Span- Figure 2. Prevalence of HIV (% of patients infected) according to sex and duration of injection drug use. (*), P for comparison of HIV-infection prevalence in men and women within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 76% in women vs. 69% in men; P p.095). (**), P for comparison of HIV-infection prevalence by sex according to 3 categories of duration of injection drug use (i.e., prevalences of HIV in women reporting 14 years, 2 4 years, or!2 years of injection drug use were 76%, 53%, and 45%, respectively; P p.001). HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S407
5 Figure 3. Prevalence of HIV (% of patients infected) according to age at start of injection drug use and duration of injection drug use. (*), P for comparison of HIV-infection prevalence by age at starting injection within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 74% if they started injection at age!18 years, 71% if they started at age years, and 61% if they started at age 121 years; P p.026). (**), P for comparison of HIV-infection prevalence by age at starting injection according to 3 categories of duration (i.e., prevalences of HIV in those starting injection at age!18 years and reporting 14 years, 2 4 years, or!2 years of injection drug use were 74%, 54%, and 41%, respectively; P p.001). ish drug users [12]. If the findings of this study regarding the prevalence of HIV relate to heavy users of injection drugs, it is probable that persons with less-severe patterns of drug abuse will show a similar reduction. Of note, the decrease in the prevalence of HIV infection is not observed in other common bloodborne infections, such as HCV, or in the percentage of chronic carriers of HBsAg. We found a consistent and gradual downward trend in HIVinfection prevalence in IDUs who began injection drug use after 1992, regardless of the age at first injection drug use and of sex, and in persons with comparable durations of injection drug use. In that year, programs of methadone substitution treatment for heroin dependence started to be generalized in the city of Barcelona, and that intervention has been one of the major initiatives in diminishing the spread of HIV [13, 14]. Despite the decrease in the prevalence of HIV infection, we Table 4. ORs for HIV infection in a cohort of 1111 injection drug users according to sex and age at start of injection drug use. Characteristic, period injection drug use started OR (95% CI) for HIV infection, by duration of injection drug use 48 months 148 months Age at start of injection drug use 21 years Before or during ( ) 4.14 ( ) 121 years Before or during ( ) 5.39 ( ) Sex Male Before or during ( ) 2.29 ( ) Female Before or during ( ) 2.73 ( ) S408 CID 2003:37 (Suppl 5) Muga et al.
6 identified 2 subsets of persons who deserve special attention because they maintain a relatively high prevalence of HIV: women and those IDUs who started injection at a young age. During the first 2 years of injection drug use, women have more than twice the prevalence of HIV infection that male IDUs have, and these differences were similar before and after The explanation for the excess of infection has been related to the high frequency of exchanging drugs for sex [15, 16] and/or of having a sex partner who is also an IDU [17]. Concerning the age of starting drug use, those who start at a younger age always show a higher prevalence of HIV. Young age is associated with high-risk behavior related to drug use, and in this regard, to delay the age of starting drug use can be favorable to the acquisition of habits that prevent the transmission of bloodborne infections [18 20]. Several limitations should be noted in this study. The external validity and generalization of results can be limited when only a single treatment center is taken into account to analyze the evolution of the HIV epidemic. In this hospital cohort, a bias in survival is possible because of the fact that IDUs could die from AIDS or overdose before admission. Last, some patients cannot assess the date when they started injection drug use, in particular those IDUs with chronic, long-term addiction. However, the recall bias is not usually observed among those who have injected drugs for only a few years. From this study, we can infer the necessity for implementing preventive interventions for female IDUs and for those young and recent initiates. Early diagnosis of the addiction, promoting harm reduction in HIV prevention, and treatment for drug abuse are effective ways to curtail the spread of HIV infection. References 1. Vigilancia epidemiológica del VIH/sida en España. Actualización a 30 de junio de Parte I. Publicacion Oficial de Seisida 2002; 13: Barrio G, de la Fuente L, Cami J. The consumption of drugs in Spain and its position in European context [in Spanish]. Med Clin (Barc) 1993; 101: Gamella JF. The spread of intravenous drug use and AIDS in a neighborhood in Spain. Med Anthropol Q 1994; 8: Egea JM, Tor J, Muga R, et al. Rates of human immunodeficiency virus (HIV) infection in intravenous drug addicts from the Barcelona area, according to sex and age of drug consumption onset [in Spanish]. Med Clin (Barc) 1996; 106: Solomon L, Astemborski J, Warren D, et al. Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993; 137: Freeman RC, Rodriguez GM, French JF. A comparison of male and female intravenous drug users risk behaviors for HIV infection. Am J Drug Alcohol Abuse 1994; 20: Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992; 18: Sabbatini A, Carulli B, Villa M, et al. Recent trends in the HIV epidemic among injecting drug users in Northern Italy, AIDS 2001; 15: Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: van Ameijden EJC, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998; 12: Muga R, Roca J, Egea JM, et al. Mortality of HIV-positive and HIVnegative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000; 23: European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drug problem in the European Union and Norway. Luxembourg: Office for Official Publications of European Communities, Available at: Accessed October Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among drug users in and out of treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr 1993;6: Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113(Suppl 1): Solomon L, Astemborski J, Warren D, et al. Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993; 137: Astemborski J, Vlahov D, Warren D, Solomon L, Nelson KE. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health 1994; 84: Barnard MA. Needle sharing in context; patterns of sharing among men and women injectors and HIV risks. Addiction 1993; 88: Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992; 18: Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000; 14: Miller CL, Tyndall M, Spittal P, Li K, LaLiberte N, Schechter MT. HIV incidence and associated risk factors among young injection drug users. AIDS 2002; 16: HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S409
HIV incidence rates among drug users in northern Thailand,
Epidemiol. Infect. (2000), 1, 153 158. Printed in the United Kingdom 2000 Cambridge University Press HIV incidence rates among drug users in northern Thailand, 1993 7 J. JITTIWUTIKARN, P. SAWANPANYALERT
More informationNOUVELLE PRÉOCCUPATION CONCERNANT LA TRANSMISSION DU VIRUS DE L HÉPATITE C CHEZ LES USAGERS DE DROGUES INJECTABLES À MONTRÉAL, CANADA
Le Colloque Européen et International THS Biarritz,11 au 14 octobre 2011 NOUVELLE PRÉOCCUPATION CONCERNANT LA TRANSMISSION DU VIRUS DE L HÉPATITE C CHEZ LES USAGERS DE DROGUES INJECTABLES À MONTRÉAL, CANADA
More informationHepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
More informationHIV-Associated Risk Behaviour Among Drug Users at Drug Rehabilitation Centres
, ORIGINAL ARTICLE HIV-Associated Risk Behaviour Among Drug Users at Drug Rehabilitation Centres M N Fauziah, MD, S Anita, MD, B N Sha'ari, MD, B I RosH, MD Introduction HIV infection and AlDS is a major
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationEstimates of New HIV Infections in the United States
Estimates of New HIV Infections in the United States Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in new HIV infections has historically
More informationDoes referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol
Does referral from an emergency department to an alcohol treatment center reduce subsequent emergency room visits in patients with alcohol intoxication? Robert Sapien, MD Department of Emergency Medicine
More informationHuman immunodeficiency virus (HIV) infection in parenteral drug users: evolution of the epidemic over 10 years
International Epidemiological Association 1999 Printed in Great Britain International Journal of Epidemiology 1999;28:335 340 Human immunodeficiency virus (HIV) infection in parenteral drug users: evolution
More informationDrug Situation in Vancouver UHRI. Report prepared by the Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS
Drug Situation in Vancouver Report prepared by the Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS Second edition June 2013 UHRI U R BAN H EALTH R ESEARCH I NITIATIVE
More informationThe use of alcohol and drugs and HIV treatment compliance in Brazil
The use of alcohol and drugs and HIV treatment compliance in Brazil André Malbergier, MD, PhD Hospital das Clínicas Medical School University of São Paulo Brasil The Casa da AIDS offers specialized integral
More information7% fewer Basque youths began drug addiction treatments between 2009 and 2010
7% fewer Basque youths began drug addiction treatments between 29 and 21 In 21, two in every thousand young people aged 15 to 29 started drug dependence treatments and, for the first time, the number of
More informationHow To Reduce High Risk Behavior In Injection Drug Users Through Syringe Exchange
Alex Willard HWP 455.002 Research Paper November 17, 2010 Reducing High Risk Behavior in Injection Drug Users Through Syringe Exchange For prevention of transmission of the Human Immunodeficiency Virus
More informationAnnual report 2009: the state of the drugs problem in Europe
Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius - 5 November 2009 Dagmar Hedrich
More informationBringing Hepatitis C Treatment into the Medical Home
Bringing Hepatitis C Treatment into the Medical Home Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission Neighborhood Health Center, San Francisco, CA The Challenge: Hepatitis C Virus
More informationPrevalence of Sexually Transmitted Infections and Associated Risk Factors among Populations of Drug Abusers
920 Prevalence of Sexually Transmitted Infections and Associated Risk Factors among Populations of Drug Abusers Lu-Yu Hwang, 1 Michael W. Ross, 1 Carolyn Zack, 1 Lara Bull, 1 Kathie Rickman, 2 and Marsha
More informationPredictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users
Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users Jennifer R. Havens, PhD, MPH Carrie B. Oser, PhD Carl G. Leukefeld, PhD Study Objective The objective
More informationEpidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
More informationInjection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results
Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results David W. Forrest, Ph.D. Marlene LaLota, M.P.H. John-Mark Schacht Gabriel A. Cardenas, M.P.H. Lisa Metsch, Ph.D. National HIV Behavioral
More informationAN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS
AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS Helgar Musyoki MARPs and Vulnerable Groups Program National AIDs/STI Control Programme November 2012 Background Injection of heroin in Kenya reportedly
More informationHuman Immunodeficiency Virus Prevention and the Potential of Drug Abuse Treatment
SUPPLEMENT ARTICLE Human Immunodeficiency Virus Prevention and the Potential of Drug Abuse Treatment David S. Metzger and Helen Navaline University of Pennsylvania/Veteran s Affairs Medical Center, Center
More informationRisk Factors for Alcoholism among Taiwanese Aborigines
Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social
More informationHepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System
Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System P.O. Box 9441 Minneapolis, MN 55440-9441 612-676-5414, 1-877-676-5414 www.health.state.mn.us/immunize
More informationJoão Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationEpidemiology of hepatitis B, hepatitis C and HIV infections among intravenous drug users in Jerusalem, Israel
International Public Health Journal ISSN: 1947-4989 Volume 2, Issue 3-Special Issue pp. 345-350 2010 Nova Science Publishers, Inc. Epidemiology of hepatitis B, hepatitis C and HIV infections among intravenous
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationInjection Drug Use, HIV and HCV Infection in Ontario: The Evidence 1992 to 2004
> Injection Drug Use, HIV and HCV Infection in Ontario: The Evidence 1992 to 2004 Peggy Millson, MD, FRCPC 1 Lynne Leonard, PhD, CQSW 2 Robert S. Remis, MD, MPH, FRCPC 1 Carol Strike, PhD 3 Laurel Challacombe,
More informationFemale drug users in European prisons EXCECUTIVE SUMMARY NOVEMBER 2004
University of Hamburg With financial support from the AGIS Programme European Commission Directorate General Justice and Home Affairs Female drug users in European prisons best practice for relapse prevention
More informationFALLING DRUG USE: THE IMPACT OF TREATMENT
We have a policy which actually is working in Britain. Drugs use is coming down, the emphasis on treatment is absolutely right, and we need to continue with that to make sure we can really make a difference.
More informationEuropean report on drug consumption rooms Executive summary
Page 1 of 7 European report on drug consumption rooms Executive summary June 2004 Dagmar Hedrich, Project Manager, P2 - Responses General public Introduction The European report on drug consumption rooms
More informationSeroprevalence and risk factors of Lassa fever infection in Nasarawa State, Nigeria 2013
Seroprevalence and risk factors of Lassa fever infection in Nasarawa State, Nigeria 2013 Muhammad Shakir Balogun COHORT 3 Nigeria-FELTP Supervisors: Dr. AT Olayinka, Dr. AI Mamman Outline Background Methodology
More informationThe VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality
The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality Federica Vigna-Taglianti www.oed.piemonte.it Piedmont Centre for Drug Addiction Epidemiology
More informationdrug treatment in england: the road to recovery
The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:
More informationWe include a series of recommended questions for the Swedish delegation at the end of our letter.
United Nations Committee on Economic Social and Cultural Rights Palais Wilson CH 1211 Geneva 10 Switzerland 2 October 2008 Re: Review of Sweden s fifth periodic report, 41 st Session of the Committee on
More informationEPIDEMIOLOGY OF HEPATITIS B IN IRELAND
EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis
More informationHIV Surveillance Update
HIV Surveillance Update Presentation to: CAPUS Metro Atlanta Testing and Linking Consortium (MATLC) Presented by: Deepali Rane, MPH and Jane Kelly, MD Georgia Department of Public Health Epidemiology Date:
More informationSyphilis on the rise again in Germany results from surveillance data for 2011
Rapid communications Syphilis on the rise again in Germany results from surveillance data for 2 V Bremer (bremerv@rki.de), U Marcus, O Hamouda. Division for HIV/AIDS, STI and Blood-borne Infections, Department
More informationHeroin smoking by chasing the dragon in young opiate users in Ireland: stability and associations with use to come down off Ecstasy
JOURAL OF SUBSTANCE ABUSE ELSEVIER Journal of Substance Abuse Treatment 20 (2001) 297-300 TREATMENT Brief article Heroin smoking by chasing the dragon in young opiate users in Ireland: stability and associations
More informationIncrease of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection?
Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection? S. Manzanares-Laya 1, P. García de Olalla 1,2, C. Garriga 1,3,
More informationDifferences in patterns of drug use between women and men
Differences in patterns of drug use between women and men Differences in patterns of drug use between women and men Key findings Introduction Cannabis Ecstasy Tranquillisers and sedatives Alcohol and drug
More informationDrug Use and Abuse in San Diego County, California: 2013
Drug Use and Abuse in San Diego County, California: 213 Karla D. Wagner, Ph.D. 1 ABSTRACT The most significant change observed in drug use/abuse indicators in San Diego County in 213 was an increase in
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationINJECTION DRUG USE AND ITS INTERVENTIONS IN AFRICA: THE FORGOTTEN CONTINENT Some Examples From Tanzania
INJECTION DRUG USE AND ITS INTERVENTIONS IN AFRICA: THE FORGOTTEN CONTINENT Some Examples From Tanzania Jessie Kazeni MBWAMBO, Senior Researcher and Psychiatrist (Muhimbili University Teaching Hospital)
More informationHepatitis Services in Substance Abuse Treatment Settings
Hepatitis Services in Substance Abuse Treatment Settings Funding provided by the Center for Substance Abuse Treatment The Matrix Institute Dan George Overview Hx of HCV group s implementation at OTP clinic
More informationAlcohol Dependence and HIV Part 1
HIV Case Conference: Management of Psychiatric Conditions Patrick Marsh, MD Faculty, Florida/Caribbean AIDS Education and Training Center Assistant Professor, College Of Medicine, Psychiatry And Behavioral
More informationBriefing Note: Hepatitis B & Hepatitis C. Summary:
Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and
More informationThe NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.
New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high
More informationBeginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice
Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:
More informationDesigning Clinical Addiction Research
Designing Clinical Addiction Research Richard Saitz MD, MPH, FACP, FASAM Professor of Medicine & Epidemiology Boston University Schools of Medicine & Public Health Director, Clinical Addiction, Research
More informationTestimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationB. SIGNIFICANCE 1. Overview: In this proposed study, risk factors instigating a young person to become an injector will be determined.
B. SIGNIFICANCE 1. Overview: Injection drug use continues to be a major risk factor for acquisition of HIV, the virus that causes AIDS. The Centers for Disease Control (CDC) reported that in the United
More information2. PROVISION OF COMBINED HEPATITIS A AND B VACCINE OR MONOVALENT HEPATITIS A OR HEPATITIS B VACCINE FOR HIGH RISK GROUPS
Guidelines for the Provision of Hepatitis A and B Vaccine to Adults in Western Australia at Risk of Acquiring these Infections by Sexual Transmission and Injecting Drug Use 1. BACKGROUND These guidelines
More informationUsing HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care
Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Anna Satcher Johnson, MPH Symposium on Measuring the HIV Care Continuum Center for AIDS Research University of Washington
More informationBloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationWISCONSIN AIDS/HIV PROGRAM NOTES
Wisconsin 2014 HIV Care Continuum: Statewide and Select Population Groups Casey Schumann, MS, AIDS/HIV Program Epidemiologist, AIDS/HIV Program, Wisconsin Division of Public Health Background The HIV care
More information24 Elisad annual meeting Arezzo 11-13 October 2012
24 Elisad annual meeting Arezzo 11-13 October 2012 From addiction to consumption: The evolution of the phenomenon and the interventions of services The big change:back to the late 90 and the zero decade
More informationOverview of Chemical Addictions Treatment. Psychology 470. Background
Overview of Chemical Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides 1 Background Treatment approaches
More informationPoor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board
Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board The growing crisis of HIV/HCV coinfection It is estimated that 4-5 million people living with HIV (PLHIV)
More informationNew York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy
New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy Policy Statement The accelerated four-dose schedule for combined hepatitis A and B vaccine
More informationMany injection drug users (IDUs) use emergency departments as a regular. Hospital utilization and costs in a cohort of injection drug users
Hospital utilization and costs in a cohort of injection drug users Anita Palepu, * Mark W. Tyndall, Hector Leon, Jennifer Muller, * Michael V. O Shaughnessy, ** Martin T. Schechter, * Aslam H. Anis Abstract
More informationBasic research methods. Basic research methods. Question: BRM.2. Question: BRM.1
BRM.1 The proportion of individuals with a particular disease who die from that condition is called... BRM.2 This study design examines factors that may contribute to a condition by comparing subjects
More informationPlacing Nation on the Path Toward the Elimination of Hepatitis C
Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for
More informationFactors Associated with Adolescent Initiation of Injection Drug Use
Cnvsrar- M. FULLER, PHD I Davro VLRHov, PUD ANrsr-ra M. ARnrA, PnD r DnxTELLE C. OMtRn, MHS RrcHano GARFETN, PHD r STETFANTB A. SrnarHDEE, PHD Factors Associated with Adolescent Initiation of Injection
More informationIN THE SENATE OF THE UNITED STATES , 2003. M. introduced the following bill; which was referred to the Committee on A BILL
DRAFT //0 0TH CONGRESS ST SESS. S. To direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive program for education, prevention, and treatment of Hepatitis
More informationHIV/AIDS: General Information & Testing in the Emergency Department
What Is HIV? HIV/AIDS: General Information & Testing in the Emergency Department HIV is the common name for the Human Immunodeficiency Virus. HIV is a retrovirus. This means it can enter the body s own
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationCourse Description. SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES
Course Description SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES At the end of this course participants will be able to: Define and distinguish between substance use, abuse and dependence
More informationPositive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationLancet Device Incident Investigation Report - 2012
Lancet Device Incident Investigation Report - 2012 Summary On May 16, 2012 the Winnipeg Regional Health Authority (WRHA) received notification from the University of Manitoba (U of M) of an incident at
More informationHow To Treat An Addictive Disorder In Criminal Justice
Medication Assisted Treatment For Opiate Addiction in Correctional Settings Jeff Baxter, MD Dept. of Family Medicine UMASS Medical School Joshua Lee, MD, MS Dept. of General Internal Medicine New York
More informationSUPPLEMENT ARTICLE METHODS
SUPPLEMENT ARTICLE Effects of Long-Term, Medically Supervised, Drug-Free Treatment and Methadone Maintenance Treatment on Drug Users Emergency Department Use and Hospitalization Barbara J. Turner, 1 Christine
More informationHospitalizations for Hepatitis A, B, and C, Active Component, U.S. Armed Forces, 1991-2011
Hospitalizations for Hepatitis A, B, and C, Active Component, U.S. Armed Forces, 1991-2011 lthough genetically quite distinct from one another, hepatitis viruses A, B, and C all cause inflammatory liver
More informationIntroduction to Substance Abuse Issues in Canada: Pathways, Health Implications and Interventions
Introduction to Substance Abuse Issues in Canada: Pathways, Health Implications and Interventions Maritt Kirst, PhD Centre for Research on Inner City Health, St. Michael s Hospital OTC Summer Institute
More informationHIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014
To protect, promote and improve the health of all people in Florida through integrated state, county, and community efforts. HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida,
More informationThe Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationFour-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection
RESEARCH REPORT Blackwell Science, LtdOxford, UKADDAddiction0965-2140 2005 Society for the Study of Addiction 100 Original Article Mortality, re-incarceration and hepatitis C infection Kate A. Dolan et
More informationAssertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia
Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia Peter Higgs, Nyree Chung, Shelley Cogger, Rebecca Winter, Margaret Hellard & Paul Dietze Acknowledgements
More informationPL-P2 Hepatitis C Treatment Expansion
POLICY LEVEL PLP2 Hepatitis C Treatment Expansion RECOMMENDATION SUMMARY TEXT The Health Care Authority (HCA) requests $77,738,000 ($20,019,000 GFState) in the 2016 Supplemental to expand treatment for
More information3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the
More informationEpidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000
More informationCompetency 1 Describe the role of epidemiology in public health
The Northwest Center for Public Health Practice (NWCPHP) has developed competency-based epidemiology training materials for public health professionals in practice. Epidemiology is broadly accepted as
More informationDrugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP
Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP Habit is habit, and not to be flung out of the window by any man, but coaxed down-stairs one step at a time. Samuel Langhorne Clemens
More informationAssessing the Costs of Medication-Assisted Treatment for HIV Prevention in Georgia
Assessing the Costs of Medication-Assisted Treatment for HIV Prevention in Georgia BACKGROUND While post-soviet Georgia has experienced favorable economic, political, and social change in the last two
More informationClinical Priorities for Alcohol and Drugs in Public Health
Clinical Priorities for Alcohol and Drugs in Public Health What do we need to Measure up to? Dr Michael Kelleher Clinical Lead Alcohol and Drugs Team, Health and Wellbeing Directorate SMMGP 8 th Primary
More informationHepatitis C. Screening, Diagnosis and Linkage to Care
Hepatitis C Screening, Diagnosis and Linkage to Care Diagnosis If your hepatitis C antibody test is reactive, a second test will be needed to diagnose and determine if you are currently infected. Screening
More informationEvidence-Based Treatment for Opiate-Dependent Clients: Availability, Variation, and Organizational Correlates
The American Journal of Drug and Alcohol Abuse, 32: 569 576, 2006 Copyright Q Informa Healthcare ISSN: 0095-2990 print/1097-9891 online DOI: 10.1080/00952990600920417 Evidence-Based Treatment for Opiate-Dependent
More informationProgram Prevention of HCV infections
Program Prevention of HCV infections The main objective of the Program is to provide a basis for planning a longterm strategy for preventing HCV and combating hepatitis C in Poland. PROGRAM SUPPORTED BY
More informationBody Fluid Exposure:
Focus on CME at the University of Manitoba Focus on CME at the University of Manitoba Body Fluid Exposure: What To Do? John Sokal, MD, CFPC Presented at Bug Day 2003, Health Sciences Centre, Winnipeg (October
More informationDrug Abuse Patterns and Trends in the San Francisco Bay Area Update: June 2014
Drug Abuse Patterns and Trends in the San Francisco Bay Area Update: June 24 Alice A. Gleghorn, Ph.D. ABSTRACT In San Francisco, increases in heroin consequence indicators (treatment admissions and Drug
More informationBLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011. 1. ABO Typing: Performed each time with each donation
Testing Performed: BLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011 1. ABO Typing: Performed each time with each donation 2. Rh Typing: o Performed along with ABO typing to determine
More informationAlcohol and drugs prevention, treatment and recovery: why invest?
Alcohol and drugs prevention, treatment and recovery: why invest? 1 Alcohol problems are widespread 9 million adults drink at levels that increase the risk of harm to their health 1.6 million adults show
More informationREVIEW OF DRUG TREATMENT AND REHABILITATION SERVICES: SUMMARY AND ACTIONS
REVIEW OF DRUG TREATMENT AND REHABILITATION SERVICES: SUMMARY AND ACTIONS 1. INTRODUCTION 1.1 Review Process A Partnership for a Better Scotland committed the Scottish Executive to reviewing and investing
More informationThe State Hospital HIV / AIDS
The State Hospital HIV / AIDS The red ribbon is the international symbol of HIV & AIDS awareness. What is HIV? HIV stands for Human Immunodeficiency Virus: H is for Human - This virus infects human beings.
More informationNational Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
More informationA P P E N D I X SAMPLE FORMS
A P P E N D I X A SAMPLE FORMS Authorization for Disclosure Consent for HBV/HCV Antigens, HIV Antibody Documentation of Staff Education Employees Eligible for Hepatitis-B Vaccination Hepatitis-A Consent
More informationTargeted HIV Testing & Enhanced Testing Technologies. HIV Prevention Section Bureau of HIV/AIDS
Targeted HIV Testing & Enhanced Testing Technologies HIV Prevention Section Bureau of HIV/AIDS May 2012 1 Typing a Question in the Chat Box Type question in here 2 Completing the Webinar Evaluation (opened
More information